Disease and Health Research: Recent Developments Vol. 3

Emphysematous pyelonephritis is a rare but life-threatening necrotising infection of the renal parenchyma and surrounding tissues, defined by the presence of gas within the collecting system, parenchyma or perinephric space. The condition occurs predominantly, although not exclusively, in patients with poorly controlled diabetes mellitus and carries a mortality that historically approached one-half of affected individuals before the modern era of early imaging, intensive supportive care and minimally invasive drainage. This review synthesises the accessible peer-reviewed literature on the classification, pathogenesis, risk stratification and management of emphysematous pyelonephritis, with particular attention to unresolved methodological and clinical controversies rather than a simple restatement of case volumes. The evidence indicates convergence around several points: computed tomography-based classification, whether the two-tier Wan system or the four-tier Huang-Tseng system, correlates broadly with prognosis; thrombocytopenia, altered consciousness, bilateral disease and shock are consistently associated with mortality across independently conducted cohorts; and a conservative-first strategy combining broad-spectrum antimicrobial therapy with percutaneous drainage has progressively displaced emergency nephrectomy as first-line management, with nephrectomy now reserved for refractory or fulminant presentations. Considerable inconsistency nevertheless persists regarding the comparative performance of the numerous prognostic scoring systems proposed over the past two decades, the true independent contribution of diabetes to mortality once confounders are accounted for, and the applicability of predominantly single-centre, retrospective evidence to varied health-system settings. Regional data, particularly from South and East Asia, illustrate both the disproportionate burden of the disease in populations with a high prevalence of diabetes and the persistent underrepresentation of such settings in pooled analyses. This review concludes that while the broad therapeutic direction of travel is reasonably well supported, the evidence base remains constrained by heterogeneous outcome definitions, retrospective design and the near-total absence of prospective comparative trials, leaving several clinically consequential questions without a definitive answer.